Defensive sectors have beaten the S&P 500 by a wide margin in recent months, even though they are priced much higher relative to earnings estimates than the index.
Johnson & Johnson offers a diversified healthcare portfolio and massive scale across its MedTech and pharmaceutical segments. Vertex Pharmaceuticals maintains a dominant position in the cystic fibrosis market while expanding into high-growth gene therapies.
Banco Santander S.A. raised its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 5.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 113,437 shares of the pharmaceutical company's stock after purchasing an additional 5,362 shares during the quarter.
Amgen maintains a massive global footprint and a highly diversified portfolio of medicines for serious conditions. Vertex Pharmaceuticals dominates the cystic fibrosis market and is expanding into gene editing and pain management.
The portfolio outperformed the Russell 2000 Index in what was a difficult period for the small cap asset class. Financials was the largest contributing sector, almost entirely due to stock selection. Top contributors include Victory Capital and Acadian Asset Management.
Allspring Global Investments Holdings LLC raised its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 11.7% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 157,086 shares of the pharmaceutical company's stock after purchasing an additional
Ethic Inc. lifted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 8.6% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 22,744 shares of the pharmaceutical company's stock after acquiring an additional 1,797 shares during the quarter. Ethic Inc.'s holdings in Vertex